What Reglan Tardive Dyskinesia Symptoms Should You Document?
From General Health Information to Occupational Exposure Concerns
If you or a loved one has taken Reglan and noticed involuntary muscle movements, you may be experiencing tardive dyskinesia. Recognizing and documenting these symptoms early is critical for proper diagnosis and care. Building on decades of research into medication-induced movement disorders, this page provides a practical checklist for organizing your medical records and understanding the clinical signs.
Reglan and Tardive Dyskinesia: Medical Evidence and Risk Context
Reglan (metoclopramide) is a medication approved for short-term treatment of symptomatic gastroesophageal reflux in adults and for relief of symptoms in adults with acute and recurrent diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The drug carries a boxed warning stating that metoclopramide, including Reglan, can cause tardive dyskinesia (TD), a potentially irreversible serious movement disorder (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The risk of developing TD increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD, and the prescribing information instructs clinicians to use Reglan for the shortest duration of treatment and to periodically reassess the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with symptomatic, documented gastroesophageal reflux, the maximum duration of Reglan treatment is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In patients with diabetic gastroparesis, the total duration of treatment with metoclopramide products, including Reglan tablets, should be avoided for longer than 12 weeks; if longer-term use is unavoidable, routine monitoring for signs and symptoms of TD is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Tardive dyskinesia is characterized by potentially irreversible and disfiguring involuntary movements of the face or tongue, and sometimes of the trunk and/or extremities (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Metoclopramide may also suppress or partially suppress the signs of TD, potentially delaying diagnosis because it can mask the underlying disease process (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The boxed warning emphasizes that if signs or symptoms of TD develop, Reglan should be immediately discontinued (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The drug is not recommended for use in pediatric patients due to the risk of TD and other extrapyramidal symptoms, as well as the risk of methemoglobinemia in neonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
Statute of Limitations for Reglan Claims in Michigan
For patients in Michigan who have developed TD after taking Reglan, the statute of limitations is a critical legal consideration. The statute of limitations sets a time limit within which a lawsuit must be filed. In Michigan, the statute of limitations for personal injury claims, including those related to prescription drug injuries, is generally three years from the date of injury or from the date the injury was discovered, or should have been discovered, through reasonable diligence. However, the specific timeline can vary based on the circumstances of each case, including when the patient first noticed symptoms of TD and when they became aware of the potential link to Reglan. Because TD can develop gradually and may be masked by the medication itself, the date of discovery can be a key factor. Patients who believe they have been harmed should consult with a legal professional experienced in pharmaceutical litigation to determine the applicable deadline for their claim. Settlement-related considerations for affected patients include the adequacy of warnings provided by the manufacturer. The boxed warning on Reglan clearly states the risk of TD and the importance of limiting treatment duration (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, patients may have been prescribed Reglan for longer than the recommended 12 weeks, or may not have been adequately informed of the risk. The timeline between exposure and documented harm is also relevant; TD can appear months or even years after starting Reglan, and the cumulative dosage is a known risk factor (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Patients who develop TD may be eligible for compensation for medical expenses, pain and suffering, and other damages. Legal counsel can help evaluate whether the manufacturer's warnings were sufficient and whether the patient's use of Reglan fell within the approved indications and duration. In summary, Reglan carries a well-documented risk of tardive dyskinesia, and the prescribing information provides clear guidance on limiting treatment duration and monitoring for symptoms. Patients in Michigan who have developed TD after using Reglan should be aware of the statute of limitations for filing a claim and should seek legal advice promptly to preserve their rights. The evidence underscores the importance of early recognition of TD symptoms and the need for careful adherence to prescribing guidelines.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the statute of limitations for Reglan-related tardive dyskinesia claims in Michigan?
In Michigan, the statute of limitations for personal injury claims, including those from prescription drug injuries, is generally three years from the date of injury or from when the injury was discovered or should have been discovered. Because TD can develop gradually and may be masked by Reglan, the discovery date is crucial. Consulting a legal professional is recommended to determine the exact deadline for your case.
Can I file a lawsuit if I developed tardive dyskinesia after taking Reglan for more than 12 weeks?
Yes, you may have a claim if you developed TD after prolonged use of Reglan. The prescribing information recommends limiting treatment to 12 weeks and monitoring for TD. If you were prescribed Reglan for longer or were not adequately warned of the risk, you may be eligible for compensation. Legal counsel can evaluate the specifics of your case.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
Related Articles
References
Request a Free Case Review
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.